Canaccord Adams reiterates its Sell rating and $23 price target on Amylin Pharmaceuticals (Nasdaq: AMLN) following news yesterday that the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE